Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$1.22 USD
+0.13 (11.93%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $1.23 +0.01 (0.82%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth F Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LXRX 1.22 +0.13(11.93%)
Will LXRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LXRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LXRX
Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know
Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates
LXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
KURA Stock Rises More Than 15% This Past Week: Here's Why
Other News for LXRX
MACD Bearish Centerline Cross appears for LXRX after 0.91% move
Lexicon Pharmaceuticals: Promising Phase 2b Results for Pilavapadin Support Buy Rating
20 Day Moving Average Resistance appears for LXRX after 1.79% move
Lexicon Pharmaceuticals (LXRX) Highlights Promising Phase 2b Study Results
Lexicon announces presents data from Phase 2 PROGRESS study for pilavapadin